Literature DB >> 33280271

Philadelphia-negative myeloproliferative neoplasms among Kuwaiti Nationals.

Salem Alshemmari1, Mazyad Almazyad2, Aisha Alwehaib2, Reem Ameen3.   

Abstract

The epidemiology, genetics, and thrombosis risk of MPNs among Arabs are largely unknown. This may be attributed to scarce epidemiological data, particularly from our region. Our study included 381 Kuwaiti nationals with Ph-negative MPNs and a confirmed driver mutation involving JAK2 (exon 12 14), CALR, or MPL. This first regional study examines the demographics, clinical parameters, and thrombosis-related attributes of the participants. This study reported a median age of 58 years, with females and males representing 54.9% and 45.1%, respectively. ET was the most frequent subtype of Ph-negative MPNs in our population, accounting for 52.0% of the cases, followed by PV, found in 34.6% of the participants, and PMF, found in 8.4% of participants. The crude annual cumulative incidence of Ph-negative MPNs in Kuwait ranged from 0.674 to 3.177 per 100,000 population across the study period. The most common driver mutation was JAK2V617F, with a frequency of 89.5%. At diagnosis, 19.2% of the patients presented with unexplained thrombosis, and almost half were of arterial origins. Males were more likely to present with arterial thrombosis than females (61.5% vs. 35.3%), whereas venous thrombotic events were more common in females than in males (47.1% vs. 17.9%; p-value = 0.025). Ph-negative MPNs in Kuwait are rare; however, thrombosis is a frequent complication, being documented in up to 19.2% of cases at presentation, more commonly at arterial sites. These findings call for thorough evaluation of patients with unexplained derangements in their hematological parameters during follow-ups.
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Myeloproliferative neoplasms; driver mutations; epidemiology

Mesh:

Substances:

Year:  2020        PMID: 33280271      PMCID: PMC7826452          DOI: 10.1002/cam4.3633

Source DB:  PubMed          Journal:  Cancer Med        ISSN: 2045-7634            Impact factor:   4.452


  23 in total

1.  Chromosome studies on normal and leukemic human leukocytes.

Authors:  P C NOWELL; D A HUNGERFORD
Journal:  J Natl Cancer Inst       Date:  1960-07       Impact factor: 13.506

2.  The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England.

Authors:  Karen J Phekoo; Mike A Richards; Henrik Møller; Steve A Schey
Journal:  Haematologica       Date:  2006-10       Impact factor: 9.941

3.  Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway.

Authors:  Christina Roaldsnes; René Holst; Henrik Frederiksen; Waleed Ghanima
Journal:  Eur J Haematol       Date:  2016-09-04       Impact factor: 2.997

4.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

5.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

6.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

7.  3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups.

Authors:  Natasha Szuber; Mythri Mudireddy; Maura Nicolosi; Domenico Penna; Rangit R Vallapureddy; Terra L Lasho; Christy Finke; Kebede H Begna; Michelle A Elliott; C Christopher Hook; Alexandra P Wolanskyj; Mrinal M Patnaik; Curtis A Hanson; Rhett P Ketterling; Shireen Sirhan; Animesh Pardanani; Naseema Gangat; Lambert Busque; Ayalew Tefferi
Journal:  Mayo Clin Proc       Date:  2019-02-26       Impact factor: 7.616

Review 8.  The epidemiology of venous thromboembolism.

Authors:  Richard H White
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690

9.  MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Authors:  Yana Pikman; Benjamin H Lee; Thomas Mercher; Elizabeth McDowell; Benjamin L Ebert; Maricel Gozo; Adam Cuker; Gerlinde Wernig; Sandra Moore; Ilene Galinsky; Daniel J DeAngelo; Jennifer J Clark; Stephanie J Lee; Todd R Golub; Martha Wadleigh; D Gary Gilliland; Ross L Levine
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

10.  A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.

Authors:  Tarinee Rungjirajittranon; Weerapat Owattanapanich; Patompong Ungprasert; Noppadol Siritanaratkul; Theera Ruchutrakool
Journal:  BMC Cancer       Date:  2019-02-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.